Table 2.
Clinical and CMR characteristics of patients from Heidelberg
| Healthy subjects n = 16 |
Amyloidosis n = 23 |
DCM n = 56 |
HCM n = 30 |
HHD n = 21 |
||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical characteristics | ||||||||||
| Age (years) | 49.3 ± 18.8 | 69.0 ± 11.3* | 54.3 ± 13.2 | 55.1 ± 15.9 | 52.6 ± 8.7 | |||||
| Gender, n (female/male) | 7/9 | 9/14 | 24/32 | 10/20 | 8/13 | |||||
| BMI (kg/m2) | 25.8 ± 3.9 | 25.4 ± 4.2 | 26.9 ± 5.1* | 27.0 ± 4.6* | 31.6 ± 6.2* | |||||
| hsTnT (pg/l) | 9.0, n = 1 | 34.8 (11–66)*, n = 9 | 24.8 (< 3–214), n = 18 | 9.8 (5–16), n = 5 | 15.0, n = 1 | |||||
| NT-proBNP (µg/ml) | < 20.0, n = 1 | 3001.6 (997–7059)*, n = 9 | 3119.0 (62–15,089), n = 9 | 204.0 (24–431), n = 5 | 408.0, n = 1 | |||||
| GFR (ml/min/1.73 m2 [CKD-EPI]) | 93.5 ± 16.8 | 67.9 ± 15.8* | 85.5 ± 17.3 | 86.9 ± 22.9 | 89.2 ± 17.2 | |||||
| Creatinine (µmol/l) | 86.1 ± 17.0 | 103.6 ± 23.8* | 91.5 ± 20.5 | 91.7 ± 25.9 | 91.7 ± 26.4 | |||||
| Hypertension, n | 4 | n = 12 | 6 | n = 12 | 19 | n = 43 | 12 | n = 19 | 20 | n = 21 |
| Diabetes mellitus, n | 2 | 2 | 1 | 0 | 3 | |||||
| Hyperlipidaemia, n | 3 | 6 | 11 | 3 | 3 | |||||
| Smoking history, n | 4 | 1 | 13 | 4 | 7 | |||||
| Familiy history of CVD | 3 | 2 | 12 | 5 | 3 | |||||
| CMR characteristics | ||||||||||
| LVEDV (ml/m2) | 77.5 ± 14.9 | 82.2 ± 17.7 | 119.9 ± 37.9* | 77.0 ± 18.7 | 80.4 ± 20.0 | |||||
| LVESV (ml/m2) | 30.6 ± 7.5 | 40.7 ± 16.2* | 74.0 ± 36.0* | 26.7 ± 11.5* | 30.5 ± 10.3 | |||||
| LVEF (%) | 60.8 ± 4.2 | 51.4 ± 11.7* | 40.3 ± 10.3* | 66.3 ± 7.7* | 62.4 ± 6.2 | |||||
| LV mass (g/m2) | 50.4 ± 12.1 | 93.2 ± 20.5* | 69.5 ± 19.9* | 78.0 ± 21.6* | 70.2 ± 19.4* | |||||
| Septal thickness (mm) | 9.4 ± 1.6 | 18.0 ± 2.6* | 9.6 ± 1.6 | 17.8 ± 3.6* | 12.9 ± 1.6* | |||||
| Native T1 value at 1.5T (ms) | 1,011.1 ± 37.9 | n = 8 | 1,164.4 ± 51.5* | n = 14 | 1,025.6 ± 35.6* | n = 23 | 1,027.4 ± 39.4* | n = 11 | 1,010.0 ± 31.1 | n = 2 |
| Native T1 value at 3T (ms) | 1,239.1 ± 43.3 | n = 8 | 1,407.3 ± 26.6* | n = 9 | 1,274.6 ± 30.2* | n = 33 | 1,270.3 ± 32.2* | n = 19 | 1,247.8 ± 35.8 | n = 19 |
Values are expressed as mean ± SD. Number of patients are presented where it differed from the patient group
BMI body mass index, hsTnT high-sensitivity Troponin T, NT-proBPN N-terminal pro b-type natriuretic peptide, GFR glomerular filtration rate, LVEDV left ventricular end-diastolic volume, LVESV left ventricular end-systolic volume, LV left ventricular, LGE late gadolinium enchancement
*p < 0.05 when compared to healthy volunteers from Table 1